BCM
AVDL

Brown Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Brown Capital Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,829,886
Closed -$13.8M – 115
2019
Q4 		$13.8M Buy
1,829,886
+133,596
+8% +$706K 0.13% 44
2019
Q3 		$7.06M Buy
1,696,290
+171,862
+11% +$430K 0.07% 46
2019
Q2 		$4.41M Buy
1,524,428
+124,421
+9% +$214K 0.04% 49
2019
Q1 		$2.02M Buy
1,400,007
+304,130
+28% +$688K 0.02% 63
2018
Q4 		$2.83M Buy
1,095,877
+85,700
+8% +$291K 0.03% 55
2018
Q3 		$4.43M Buy
1,010,177
+51,315
+5% +$277K 0.04% 51
2018
Q2 		$5.88M Buy
958,862
+46,164
+5% +$324K 0.06% 49
2018
Q1 		$6.65M Buy
912,698
+27,652
+3% +$243K 0.08% 50
2017
Q4 		$7.26M Buy
885,046
+8,091
+0.9% +$75.9K 0.09% 48
2017
Q3 		$9.21M Buy
876,955
+5,488
+0.6% +$52.4K 0.11% 47
2017
Q2 		$9.61M Sell
871,467
-92,514
-10% -$929K 0.12% 47
2017
Q1 		$9.33M Sell
963,981
-5,681
-0.6% -$56.8K 0.12% 47
2016
Q4 		$10.1M Buy
969,662
+43,103
+5% +$474K 0.15% 47
2016
Q3 		$11.5M Buy
926,559
+136,353
+17% +$1.78M 0.17% 47
2016
Q2 		$8.49M Buy
790,206
+211,392
+37% +$2.25M 0.13% 53
2016
Q1 		$6.39M Buy
578,814
+357
+0.1% +$3.55K 0.11% 63
2015
Q4 		$7.06M Buy
578,457
+24,398
+4% +$380K 0.11% 67
2015
Q3 		$9.04M Sell
554,059
-7,967
-1% -$175K 0.15% 61
2015
Q2 		$11.9M Buy
562,026
+13,581
+2% +$244K 0.2% 59
2015
Q1 		$9.86M Hold
548,445
– – 0.16% 65
2014
Q4 		$9.39M Sell
548,445
-13,133
-2% -$188K 0.16% 66
2014
Q3 		$8.04M Buy
561,578
+17,835
+3% +$256K 0.14% 76
2014
Q2 		$8.16M Buy
543,743
+51,458
+10% +$621K 0.14% 77
2014
Q1 		$6.6M Buy
492,285
+914
+0.2% +$9.8K 0.11% 80
2013
Q4 		$3.96M Sell
491,371
-3,531
-0.7% -$24.9K 0.06% 88
2013
Q3 		$3.25M Sell
494,902
-21,393
-4% -$132K 0.06% 90
2013
Q2 		$3.17M Buy
+516,295
New +$2.67M 0.07% 90

Other funds holding AVDL

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Brown Capital Management's AVDL Position: Q1 2020 in Review

Brown Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2020, closing a stake of 1,829,886 shares — an estimated $13.8M sold.

Brown Capital Management first reported a position in AVDL in Q2 2013 and held it in 27 quarters. The position peaked at $13.8M in Q4 2019. 56 funds tracked by Wall St. Rank hold AVDL as of Q1 2020.

  • Brown Capital Management reported no remaining Avadel Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Brown Capital Management sold 1,829,886 Avadel Pharmaceuticals shares in Q1 2020, an estimated $13.8M.
  • Brown Capital Management first reported a position in Avadel Pharmaceuticals in Q2 2013 and held it in 27 quarters.
  • Brown Capital Management's Avadel Pharmaceuticals position peaked at $13.8M in Q4 2019.
  • 56 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2020.

Based on Brown Capital Management's 13F filing for Q1 2020, filed 8 May 2020.